Condition: Lymphedema · Sponsor: Advanced Reconstructive Surgery Alliance
Lymphedema affects millions and currently lacks effective drug treatments, relying mainly on compression therapy. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown potential in managing obesity and diabetes, which can worsen lymphedema. Although anecdotal evidence suggests benefits of GLP-1 RAs for lymphedema patients, rigorous prospective studies are lacking. This study aims to evaluate the effectiveness of GLP-1 RAs in improving quality of life and clinical outcomes in lymphedema patients, thereby addressing a critical gap in literature and potentially offering a new treatment option.
This description comes directly from the study's public registry record.
Giana Truax · 866-266-2577 · gtruax@sycamoremm.com
Saba Tasawar · 732-741-0970 · stasawar@sycamoremm.com
Always discuss trial participation with your own doctor first.
| River Center | Red Bank, New Jersey, United States | Recruiting |
| 260 Old Hook Rd Suite 304 | Westwood, New Jersey, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07012642